Ramelteon used to treat insomnia can reduce the occurrence of osteoporosis
Özet
Aim: Melatonin promoted osteoblast differentiation and causes an increase in levels
of markers of bone differentiation and proliferation. Ramelteon (RAMEL) activates
melatonin receptors and binds to these receptors as non-selective. In this study, we
investigated the preventive effects of the melatonin agonist RAMEL on osteoporosis
by radiological, histological, and molecularly.
Methods: Groups 1: Control, Group 2: Osteoporosis: Overectomized group (OP),
Group 3: OP + ramelteon 2 mg/kg, Group 4: OP + ramelteon 4 mg/kg. 24 animals
underwent bilateral ovariectomy. RAMEL was administered orally once a day in the
prophylactic treatment mode for 8 weeks, 6 weeks after ovariectomy.
Results: Fourteen weeks after ovariectomy, there was a significant reduction in
femoral bone mineral density (BMD) (g/cm2) in the OP group compared to the control
group. Compared to the OP group, RAMEL treatment significantly increased the BMD
level (p<0.05). Bone matrix protein 2 (BMP2) and runt-related transcription factor 2
(RUNX2) mRNA levels were significantly lower in the OP group than in the control
group (p<0.05). RUNX2 and BMP2 mRNA levels were significantly higher in the
RAMEL treatment groups than in the OP group (p<0.05).
Conclusion: To take advantage of the peripheral effects of melatonin, RAMEL, a
peripheral melatonin agonist, can be used to prevent osteoporosis.
Kaynak
Acta Medica AlanyaCilt
5Sayı
2Bağlantı
https://dergipark.org.tr/tr/download/article-file/1775561https://hdl.handle.net/20.500.12868/1713